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http://dx.doi.org/10.1016/j.ijsu.2013.09.016“Because professionals sometimes do more harm than good when
they intervene in the lives of other people, their policies and
practices should be informed by rigorous, transparent, up-to-date
evaluations”11. Challenges in modern surgical research
Surgery hasmademassive advances in the last 50 years. Much of
this progress however has not been within the context of trans-
parent, robustly planned, conducted and reported research designs.
Many characteristics and complexities inherent in surgical innova-
tion have made it more difﬁcult for surgeons than for pharmaceu-
tical innovators to build their research systematically through to a
well-conducted deﬁnitive randomised controlled trial (RCT).2
In the modern era of evidence-based health care, where practice
is based on the results of ethical and fair “randomised” tests of new
treatments, the ﬁeld of surgery has been underperforming. Assess-
ment of surgical techniques is complicated by the constant impro-
visation and “tinkering” required of surgeons in the ﬁeld,
compounded by the complexity of deﬁning the surgical interven-
tion, the involvement of learning curves, attributes of individual
practitioners and lack of agreed standard outcomes of surgery.
Commonly there is a lack of equipoise due to preferences by both
surgeons and patients. Historically, surgical research has suffered
from a lack of funding, patchy regulation, the absence of an
embedded culture of research and a lack of training in research
methods. The consequence has been an underrepresentation of
randomised trials in surgery.3,4 Only 3.4% of articles published in
5 leading surgical journals between 1966 and 2000 were RCTs.5
Encouragingly there has been improvement in more recent de-
cades. In a review of 1058 papers published in The Journal of
Bone and Joint Surgery (American Volume) in 1975, 1985, 1995,
and 2005 articles were scored according to The Journal’s levels of
evidence for a primary research question. The percentage of
Level-I studies increased from 4% in 1975 to 21% in 2005 indicatingciates Ltd. Published by Elsevier Ltthe level of evidence in The Journal has improved signiﬁcantly over
the last thirty years.6
Problems in the surgical evidence base have been compounded
by shortcomings in both the methodological and reporting qual-
ity7e11 in journals. This is despite the existence of relevant report-
ing guidelines such as the Consolidated Standards of Reporting
Trials (CONSORT) for non-pharmacological interventions12 and
other useful resources collated on the EQUATOR Network website
(www.equator-network.org). How can we improve matters?
2. The IDEAL collaboration
The IDEAL (Idea, Development, Exploration, Assessment, Long-
term follow-up) Collaboration (www.ideal-collaboration.net) is an
open network directed by an international Steering Group of sur-
geons and researchers in surgical and other innovative complex in-
terventions, research methodologists, statisticians, journal editors
and experts in the translation of research into clinical practice.
The mission of the Collaboration is to enable surgery to develop a
solid evidence base so that patients experience good outcomes
from surgery and that unnecessary harm and waste are avoided.13
It has three main areas of activity; research to develop and vali-
date the IDEAL framework and recommendations (described
below), education to spread knowledge of the best research and
reporting methods through website resources and publications,
and advocacy for proposed initiatives which would improve the
environment for surgical research. The latter would include facili-
tating the development of a ﬁrst-in-man registry.
The IDEAL Collaboration grew out of an earlier initiative known
as the Balliol Group who held a series of conferences at Balliol Col-
lege, Oxford in 2007e2009with a commitment to improve the qual-
ity of research in surgery. Their discussions led to the development
of the IDEAL framework for describing the stages of development of
surgical and interventional innovations, and a series of recommen-
dations about howmethodology and reporting of research at each of
these stages could be improved. The group alsomade a series of pro-
posals about how speciﬁc groups (publishers, funders, regulators,
and professional organisations) can help to change the environment
for this kind of research in a positive manner.14e16
3. The IDEAL framework and recommendations: tailoring
study design to each stage of surgical innovation
IDEAL is a framework for helping to test and introduce new
techniques and treatments in a staged way, allowing for accruald. All rights reserved.
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improving study designs target each stage of surgical innova-
tion.17e19 The characteristics for each phase have been summarised
and the recommended IDEAL study design for each phase outlined
(Tables 1 and 2 available at http://www.ideal-collaboration.net/
about-ideal/ideal-summary-tables/and pdf http://www.ideal-
collaboration.net/wp-content/uploads/2013/07/IDEAL_Summary-
Tables-_FINALJuly2013docx.pdf).3.1. Idea stage (professional innovation database)
The key recommendations at this stage are:
 Mandatory registry for ﬁrst-in-man interventions, with a
conﬁdential reporting option.
 Planned research programmes for ﬁrst-in-man studies with
protocols pre-registered on the above registry.
 Development andwidespread use of agreed reporting standards
with deﬁnitions for key outcomes/modifying factors.
An example at this stage is stem cell tracheal transplant.203.2. Development stage (prospective development studies)
This stage most clearly differentiates the pathway between phar-
maceutical and surgical interventions in that the latter involves
rapid iterative changes in response to experience. It is the most
problematic of the stages and has been the most poorly reported
historically in the style of selective retrospective surgical case series.
Key recommendations aim to enhance transparency:
 Prospective studies with sequential reporting of all cases and
outcomes without omissions.
 Clear explanations of when and how technique, design or in-
dications were changed.
 Sequential presentation of results may also reveal effects of
operator learning curves.
 Prospective development studies should be externally regis-
tered, gain prior ethical approval and be fully reported.
An example of this type of model is the FDA regulatory frame-
work for implantable devices.21 Full reports of IDEAL prospective
development studies are now being published.22,23 We anticipateTable 1
Deﬁning characteristics of IDEAL framework phases.
Phase 1
Idea
Phase 2a
Development
Phase 2b
Exploration
Phase 3
Assessment
Phase 4
Long-term
monitoring
Initial report
Innovation
may be
planned,
accidental
or forced
Focus on
explanation
and
description
“Tinkering”
(rapid iterative
modiﬁcation of
technique and
indications)
Small
experience
from one centre
Focus on
technical
details and
feasibility
Technique now
more stable
Replication by
others
Focus on
adverse effects
and potential
beneﬁts
Learning curves
important
Deﬁnition and
quality
parameters
developed
Gaining wide
acceptance
Considered as
possible
replacement for
current
treatment
Comparison
against current
best practice
Monitoring
late and
rare
problems,
changes in
usemore such examples as journals positively discriminate in favour
of prospective development studies in preference to retrospective
case series.
3.3. Exploration stage (phase IIS study)
During the exploration phase of a new procedure data should be
captured systematically from every patient having the procedure in
a database to help strengthen consensus about its potential use. To
bridge the gap between non-randomised database studies and
multi-centre RCTs IDEAL suggests the greater use of “phase IIS”
transition designs, which are prospective non-randomised co-oper-
ative studies explicitly designed to contribute towards planning a
future RCT. The objectives of such a study include documenting
learning curves, determining likely treatment effects to enable po-
wer calculations for RCTs, to allow development on clarifying the
clinical question and to develop quality outcome measures for
the procedure. Several examples have demonstrated the utility of
this approach towards developing a large RCT including an Italian
study of radical gastrectomy,24 the International Registry of Acute
Aortic Dissection,25 the American College of Surgeons National pro-
gramme for surgical quality improvement26 and the recently UK
HTA-funded feasibility trial The ROMIO trial. (Randomised Oeso-
phagectomy: Minimally Invasive or Open, a feasibility study is uti-
lising this design) (http://www.hta.ac.uk/2827).
3.4. Assessment stage (surgical RCT)
Despite uncertainty in the past a consensus has emerged in
favour of accepting properly controlled trials as the gold standard
for surgery. Themain difﬁculties surgical trials need to address arise
primarily from 3 inter-related issues: deﬁnition of the intervention,
characteristics around who delivers the intervention and treatment
preferences of surgeons and patients.19 Other important areas
addressed by IDEAL study designs include additions to RCT designs
such as learning curve evaluation and quality control and compli-
ance measures. Quality control in rectal cancer surgery has recently
been reviewed in this respect.27 IDEAL recognises that while an RCT
is preferred a high quality observational studymaybe acceptable if a
trial is not feasible or rarely if deemed not necessary.
3.5. Long-term monitoring (prospective registries)
Well-designed, large observational studies utilising registries
can evaluate procedures in the long-term phase. They can provide
data for outcomes in patient subgroups and rare endpoints in safety
and effectiveness. Examples include the FDA framework for evalu-
ation of implantable devices28 and the examination of failure rates
of stemmed metal-on-metal hip replacements by analysis of data
from the National Joint Registry of England and Wales.29
4. Improved reporting of surgical research is an important
focus of IDEAL
All the phases outlined above emphasise ways to improve
transparency in reporting of surgical research. These include the
mandatory registration of procedures thought to be ﬁrst-in-man
with a conﬁdential reporting option for adverse outcomes (as in
aviation) and registries for surveillance of speciﬁc established
techniques.30 There should be well developed and agreed report-
ing standards in journals and other publications and agreed deﬁ-
nitions for key outcome measures of surgery. There should also
be reporting of continuous quality control measures for example,
CUSUM statistical technique during exploration to long-term
follow-up stages.
Table 3
Proposals for action by stakeholders in surgical research.
Stakeholder
group
Proposals for action to improve surgical research
Journal editors  Promotion of IDEAL design and reporting standards in
instructions to authors
 Assistance by editors with development of registries of
surgical protocols and reports
 Calls for speciﬁc prospective study designs
Research
funders
 Provide speciﬁc funding for well-designed early-stage
surgical innovation
 Demand evidence of beneﬁt for new techniques
 Link funding to adequate scientiﬁc evaluation
 Support well-designed surgical databases, registries, and
reporting systems
Regulators  Provide rapid, ﬂexible, and expert ethical oversight for
early-stage innovation
 Link provisional approval to evaluation or registration of
all cases
 Accept IDEAL approved study designs as evidence of
appropriate evaluation
 Raise burden of proof for full licensing of new devices to
demonstrate efﬁcacy level
Professional
societies
 Ensure guidelines explicitly support IDEAL model of
technical development and evaluation
 Require members to use appropriate registers for the
various stages of innovation as a condition of specialist
recognition
 Ensure young trainees receive education and training in
the IDEAL methods
Table 2
Key recommendations for research design at each IDEAL phase.
Idea
Professional innovation
database
Development
Prospective development
studies
Exploration
Phase IIS study
Assessment
Surgical RCT
Long-term monitoring
Prospective registries
Compulsory reporting
of all new
innovations
Conﬁdential entry
allowed to
encourage reporting
of failed innovations
(similar to CHRP
system)
Hospital or institution
to be informed
separately as a
professional duty
Detailed description of
selection criteria
Detailed technical
description
Prospective account of ALL
cases consecutively,
including those NOT
treated with new
technique/device
Clear standardised
deﬁnitions of outcomes
reported
Description of ALL
modiﬁcations, and when
they were made during the
series
Registration of PROTOCOL
before study starts
Use of Statistical Process
Control (SPC) methods to
evaluate progress
To evaluate technique
prospectively and co-
operatively
To develop a consensus
over deﬁnition of the
procedure, quality
standards and
indications
To gather data for
power calculations
To evaluate and
monitor learning curves
To achieve consensus
on the trial question
To develop a multi-
centre randomised trial
(RCT)
RCT e question agreed
in Phase IIS
Use power calculations
from Phase IIS
Use learning curve data
to decide entry points
for clinicians
Use Phase IIS consensus
to deﬁne operation,
quality control AND
outcome measures
Use modiﬁed RCTs or
recognised alternative
if RCT not feasible:
Feasibility RCT
Expertise-based RCT
Cohort multiple RCT
Step-wedge design
Controlled-interrupted
time series
Should monitor
indications as well as
outcomes
SPC used for quality
control (Shewart
charts, CUSUM, VLAD)
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research
Achieving improved standards in the development, testing and
reporting of surgical innovation in all the areas outlined above will
require a cultural change with clear roles for a variety of stake-
holders involved in the process including publishers, research
and service funders, regulators and professional societies. Table 3
(available at http://www.ideal-collaboration.net/about-ideal/
ideal-summary-tables/) outlines IDEAL proposals for action by
each group which would facilitate improvements.
5.1. Journal editors
Just as journal editors have contributed to the now widespread
practice of prospective registration of RCTs and adherence to
reporting guidelines by requiring these standards of authors, edi-
tors of journals publishing surgical research should actively pro-
mote awareness of IDEAL and its reporting and design standards.
Speciﬁcally journals could encourage submission of manuscripts
using the IDEAL recommended designs at all stages by inclusion
of IDEAL guidance in their instructions to authors. Journals could
also assist with the development of registries of surgical protocols
and reports and call for speciﬁc prospective study designs. A num-
ber of leading journals have supported dissemination of the IDEAL
framework by publishing key IDEAL papers including the BMJ, Lan-
cet, and World Journal of Urology.
5.2. IJS and IDEAL
The IJS supports improved reporting quality of surgical research.
We have endorsed CONSORT, adjusted our instructions to authors
and submission policies and republished reporting guidelines like
CONSORTand PRISMA. Since Feb 2013 at the IJS, wemade it manda-
tory for research studies to follow the appropriate reporting stan-
dard commensurate with its study design. So observationalstudies must submit a completed STROBE checklist and RCTs a
completed CONSORT checklist etc. We engineered this system by
changing the author submission gateway. Manuscripts can no
longer be submitted without completing the relevant reporting
criteria. The act of completing such checklists in our experience
brings authors manuscripts in line with the criteria themselves.
Transparency has also been enhanced over the years by the manda-
tory publication of conﬂicts of interest, ethical approval, source of
funding, trial registration and contributorship statements.
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numerous registries including ISRCTN.
(http://isrctn.org) and ClinicalTrials.gov (http://clinicaltrials.
gov). However, the registration of prospective, non-randomised
studies and their protocols is an area that needs development
and journals and publishers should collaborate to develop these.
Once set-up, as with reporting criteria progressive journals will
increasingly campaign and potentially insist on an IDEAL frame-
work for the introduction of new techniques and technologies.
The IJS plans to lead in this area byworkingwith IDEAL to pilot stra-
tegies to encourage studies conducted and reported using the
IDEAL recommendations.
5.3. Research funders
Bodies funding health care and clinical research whether public
or private are responsible for judicious allocation of funds aimed at
optimising the best evidence-based care. In relation to surgery
research funders should recognise the unique nature of surgical
innovation and provide speciﬁc funding for well-designed early-
stage studies in line with IDEAL recommended designs, link fund-
ing to adequate scientiﬁc evaluation and support well-designed
surgical databases, registries, and reporting systems. A variety of
funders should take responsibility for this. One example of how
funders have supported IDEAL design studies is illustrated by the
research development pathway examining HIFU to deliver focal
therapy for prostate cancer.
Focal therapy offers the possibility of cancer control, without the
side effect proﬁle of radical therapies. INDEX is a prospective,
multi-centre, single-arm, therapeutic, investigator-led study,31
conforming to Stage 2b (a Phase IIS Study) of the IDEAL framework.
It is funded by the Medical Research Council (UK) with commercial
support from SonaCare Medical LLC (Charlotte, North Carolina,
USA), for infra-structural study costs through an unrestricted grant
made to University College London. The design of INDEX was
informed by the reports of earlier registered studies
(NCT00561314, NCT00561262) that evaluated different approaches
to focal therapy. A two-centre, IDEAL prospective development
study was funded by the Medical Research Council (UK), Pelican
Cancer Foundation, and St Peters Trust.23 Prior work was supported
by the MRC (UK), Pelican Cancer Foundation (charity), Prostate
Research Campaign United Kingdom (charity), the Prostate Cancer
Research Centre at University College London and St. Peters Trust,
and by the UKNIHR UCL Comprehensive Biomedical Research
Centre.32
5.4. Regulators
National regulatory and advisory bodies could help to raise the
quality of evidence in surgical innovation by providing rapid, ﬂex-
ible, and expert ethical oversight for early-stage innovation (dele-
gated to a simpliﬁed local committee level), linking provisional
approval to evaluation or registration of all cases, by accepting
and recommending IDEAL approved study designs as evidence of
appropriate evaluation, and by raising the burden of proof for full
licensing of new devices to demonstration of efﬁcacy level, and
not just safety. The FDA has made the greatest move towards this
model to date.33,34
5.5. Professional societies
Finally professional societies have a big role to play in setting the
culture, standards and norms of surgical practice and research and
in training the next generation of surgeons. Guidelines from
specialist bodies are very inﬂuential and an important tool toexplicitly support the IDEAL model of technical development and
evaluation. Surgical societies might also require their members to
use appropriate registries for the various stages of innovation as a
condition of specialist recognition or research award. Whilst this
level of change is yet to happen a number of professional societies
are engaging with the IDEAL Collaboration. The Royal College of
Surgeons of England has hosted a workshop with IDEAL (http://
www.rcseng.ac.uk/surgeons/research/surgical-research/docs/
ProgrammeforHealthServiceDeliveryinSurgeryv6.pdf/view) and
several have linked to IDEAL from their websites (e.g., BASO,
BCGS, BOA, and ACPGBI). In addition other inﬂuential organisations
are endorsing IDEAL by linking from their websites including CON-
SORT (www.consort-statement.org) SPIRIT (www.spirit-statement.
org) James Lind Library (www.jameslindlibrary.org) and the EQUA-
TOR Network (www.equator-network.org).
6. Future steps: moving surgical research forward
IDEAL now wishes to work with all stakeholder groups to take
action on these proposals, especially to move the research agenda
forward. The Collaborationwebsite is in the early stages of develop-
ment (www.ideal-collaboration.net). It plans to build a library of
relevant materials, provide regular postings and newsletters about
current activities in the area and crucially will act as a portal for
interaction between all those interested in progressing research
and surgical innovation. Stakeholders are encouraged to visit the
site, register their interest and participate in improving surgery.
In particular we seek partnership with surgeons planning studies
on surgical innovation in each stage and can offer co-design and
support in funding applications and reporting with the advantage
of compliance with a recognised framework.
We plan to develop a network of IDEAL experts in major
research centres and speciality organisations globally. It is also a
priority to evaluate the IDEAL framework. This will include gath-
ering qualitative reports on the beneﬁts and difﬁculties and evalu-
ating study quality according to an appropriate guideline/measure
to be developed. The ultimate goal is to facilitate an identiﬁable
improvement in research and practice in surgery through the
collaborative efforts of IDEAL members.
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